文献速递乳腺癌

预测三阴性乳腺癌新辅助化疗后高TILs及结局的四基因特征

A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

研究基于99例治疗前样本构建了预测新辅助化疗后高肿瘤浸润淋巴细胞(TILs)的四基因特征(HLF、CXCL13、SULT1E1、GBP1),并在训练集(n=99)和独立验证集(n=115)中评估其对远处无复发生存(DRFS)的预后价值。多因素分析显示该特征与DRFS显著相关,训练集HR为0.28(95%CI 0.13-0.63),验证集HR为0.17(95%CI 0.06-0.43),且较临床病理模型提供额外预后信息。

要点

  • 四基因特征可预测三阴性乳腺癌含蒽环类新辅助化疗后高TILs。
  • 训练集多因素分析中特征与DRFS相关,HR 0.28(95%CI 0.13-0.63)。
  • 验证集多因素分析中特征与DRFS显著相关,HR 0.17(95%CI 0.06-0.43)。

核心结论

  • 四基因特征可预测三阴性乳腺癌患者含蒽环类新辅助化疗后高TILs水平及结局,并在诊断时为临床病理模型增加预后信息。

研究设计与样本

  • 利用99例治疗前样本构建与化疗后高TILs相关的四基因特征,并在训练集(n=99)和独立验证集(n=115)中评估其对DRFS的预后价值。

主要发现

  • 四基因特征结合HLF、CXCL13、SULT1E1和GBP1表达水平,在基线样本中预测新辅助化疗后淋巴细胞浸润程度。
  • 训练集多因素分析中,四基因特征与DRFS相关,HR为0.28(每增加一个单位,95%CI 0.13-0.63)。
  • 验证集多因素分析中,四基因特征与DRFS显著相关,HR为0.17(95%CI 0.06-0.43)。
  • 与临床病理治疗前模型相比,四基因特征提供显著额外预后信息,训练集似然比检验P=0.004,验证集P=0.002。

临床怎么用

  • 该四基因特征可用于预测三阴性乳腺癌患者含蒽环类新辅助化疗后高TILs及预后,并为临床病理模型增加预后信息。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with triple-negative breast cancer (TNBC), the extent of tumor-infiltrating lymphocytes (TILs) in the residual disease after neoadjuvant chemotherapy (NACT) is associated with better prognosis. Our objective was to develop a gene signature from pretreatment samples to predict the extent of TILs after NACT and then to test its prognostic value on survival. PATIENTS AND METHODS: Using 99 pretreatment samples, we generated a four-gene signature associated with high post-NACT TILs. Prognostic value of the signature on distant relapse-free survival (DRFS) was first assessed on the training set (n = 99) and then on an independent validation set (n = 115). RESULTS: A four-gene signature combining the expression levels of HLF, CXCL13, SULT1E1, and GBP1 was developed in baseline samples to predict the extent of lymphocytic infiltration after NACT. In a multivariate analysis performed on the training set, this signature was associated with DRFS [hazard ratio (HR): 0.28, for a one-unit increase in the value of the four-gene signature, 95% confidence interval (CI): 0.13-0.63)]. In a multivariate analysis performed on an independent validation set, the four-gene signature was significantly associated with DRFS (HR: 0.17, 95% CI: 0.06-0.43). The four-gene signature added significant prognostic information when compared with the clinicopathologic pretreatment model (likelihood ratio test in the training set P = 0.004 and in the validation set P = 0.002). CONCLUSIONS: A four-gene signature predicts high levels of TILs after anthracycline-containing NACT and outcome in patients with TNBC and adds prognostic information to a clinicopathological model at diagnosis.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Criscitiello C, Bayar MA, Curigliano G, et al. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Ann Oncol. 2018. PMID: 29077781. doi:10.1093/annonc/mdx691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。